BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 12783219)

  • 1. Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients.
    Jarzab B; Handkiewicz-Junak D; Roskosz J; Puch Z; Wygoda Z; Kukulska A; Jurecka-Lubieniecka B; Hasse-Lazar K; Turska M; Zajusz A
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1077-86. PubMed ID: 12783219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
    Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
    Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy.
    de Keizer B; Brans B; Hoekstra A; Zelissen PM; Koppeschaar HP; Lips CJ; van Rijk PP; Dierckx RA; de Klerk JM
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):367-73. PubMed ID: 12634964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human TSH in radioiodine treatment of differentiated thyroid cancer.
    Kovatcheva RD; Hadjieva TD; Kirilov GG; Lozanov BS
    Nucl Med Rev Cent East Eur; 2004; 7(1):13-9. PubMed ID: 15318305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of recombinant human TSH aided radioiodine doses administered in patients with differentiated thyroid carcinoma.
    Pitoia F; Tamer EE; Schere DB; Passerieu M; Bruno OD; Niepomniszcze H
    Medicina (B Aires); 2006; 66(2):125-30. PubMed ID: 16715760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recombinant human TSH stimulation in radioiodine treatment of disseminated differentiated thyroid cancer--update of current and our own experiences].
    Hasse-Lazar K; Handkiewicz-Junak D; Roskosz J; Szpak-Ulczok S; Krajewska J; Jurecka-Lubieniecka B; Jarzab B
    Endokrynol Pol; 2006; 57(4):445-50. PubMed ID: 17006851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
    de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
    J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone.
    Berg G; Lindstedt G; Suurküla M; Jansson S
    J Endocrinol Invest; 2002 Jan; 25(1):44-52. PubMed ID: 11883865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Examining recombinant human TSH primed ¹³¹I therapy protocol in patients with metastatic differentiated thyroid carcinoma: comparison with the traditional thyroid hormone withdrawal protocol.
    Rani D; Kaisar S; Awasare S; Kamaldeep ; Abhyankar A; Basu S
    Eur J Nucl Med Mol Imaging; 2014 Sep; 41(9):1767-80. PubMed ID: 24687139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
    Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
    Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose.
    Campennì A; Amato E; Laudicella R; Alibrandi A; Cardile D; Pignata SA; Trimarchi F; Ruggeri RM; Auditore L; Baldari S
    Endocrine; 2019 Jul; 65(1):132-137. PubMed ID: 30875058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human TSH and ablation of post-surgical thyroid remnants in differentiated thyroid cancer: the effect of pre-treatment with furosemide and furosemide plus lithium.
    Barbaro D; Grosso M; Boni G; Lapi P; Pasquini C; Orsini P; Turco A; Meucci G; Marzola MC; Berti P; Miccoli P; Mariani G; Rubello D
    Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):242-9. PubMed ID: 19760415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
    Vrachimis A; Schober O; Riemann B
    Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures.
    Giovanella L; Ceriani L; Ghelfo A; Keller F; Sacchi A; Maffioli M; Spriano G
    Clin Chem Lab Med; 2006; 44(5):648-52. PubMed ID: 16681439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human thyrotropin in follow-up of patients with differentiated thyroid cancer.
    Podoba J
    Bratisl Lek Listy; 2010; 111(1):38-40. PubMed ID: 20429310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH.
    Lippi F; Capezzone M; Angelini F; Taddei D; Molinaro E; Pinchera A; Pacini F
    Eur J Endocrinol; 2001 Jan; 144(1):5-11. PubMed ID: 11174831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
    Mazzaferri EL; Kloos RT
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.
    Ma C; Xie J; Liu W; Wang G; Zuo S; Wang X; Wu F
    Cochrane Database Syst Rev; 2010 Nov; 2010(11):CD008302. PubMed ID: 21069705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.